Viking Therapeutics
VKTX
391 hedge funds and large institutions have $2.02B invested in Viking Therapeutics in 2025 Q2 according to their latest regulatory filings, with 82 funds opening new positions, 149 increasing their positions, 109 reducing their positions, and 59 closing their positions.
137% more call options, than puts
Call options by funds: $231M | Put options by funds: $97.6M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 59
37% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 109
7% more capital invested
Capital invested by funds: $1.88B → $2.02B (+$140M)
5% more funds holding
Funds holding: 372 → 391 (+19)
1.45% less ownership
Funds ownership: 69.28% → 67.83% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$33.2M |
| 2 |
Two Sigma Advisers
New York
|
+$28.7M |
| 3 |
Millennium Management
New York
|
+$18.1M |
| 4 |
Citigroup
New York
|
+$16.4M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$43.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.6M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$26.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.5M |
| 5 |
BlackRock
New York
|
-$14.2M |
VKTX Hedge Fund Activity: Q2 2025 in Review
391 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2025, worth a combined $2.02B — up 7.5% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new VKTX positions and 59 closed out — a net gain of 23 holders — while 149 added to existing stakes and 109 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $33.2M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $43.4M sold.
- 391 institutional investors held Viking Therapeutics (VKTX) as of Q2 2025, up from 372 in Q1 2025.
- Funds reported $2.02B of Viking Therapeutics stock for Q2 2025, up 7.5% quarter-over-quarter.
- 82 funds opened new Viking Therapeutics positions in Q2 2025 and 59 closed out, a net change of +23 holders.
- The largest Viking Therapeutics buyer in Q2 2025 was Two Sigma Investments, an estimated $33.2M added.
- The largest Viking Therapeutics seller in Q2 2025 was Balyasny Asset Management, an estimated $43.4M sold.
Based on aggregated 13F filings for Q2 2025.